These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 22553244)

  • 1. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
    Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
    J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
    Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
    J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.
    Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM
    J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
    Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
    J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia.
    Tropé A; Sjøborg K; Eskild A; Cuschieri K; Eriksen T; Thoresen S; Steinbakk M; Laurak V; Jonassen CM; Westerhagen U; Jacobsen MB; Lie AK
    J Clin Microbiol; 2009 Aug; 47(8):2458-64. PubMed ID: 19535524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
    Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
    J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
    Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
    Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
    Liu TY; Xie R; Luo L; Reilly KH; He C; Lin YZ; Chen G; Zheng XW; Zhang LL; Wang HB
    J Virol Methods; 2014 Feb; 196():120-5. PubMed ID: 24216236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy.
    Sørbye SW; Arbyn M; Fismen S; Gutteberg TJ; Mortensen ES
    PLoS One; 2011; 6(10):e26022. PubMed ID: 21998748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
    Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
    J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women.
    Giorgi Rossi P; Carozzi F; Ronco G; Allia E; Bisanzi S; Gillio-Tos A; De Marco L; Rizzolo R; Gustinucci D; Del Mistro A; Frayle H; Confortini M; Iossa A; Cesarini E; Bulletti S; Passamonti B; Gori S; Toniolo L; Barca A; Bonvicini L; Mancuso P; Venturelli F; Benevolo M;
    J Natl Cancer Inst; 2021 Mar; 113(3):292-300. PubMed ID: 32745170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia.
    Andersson E; Kärrberg C; Rådberg T; Blomqvist L; Zetterqvist BM; Ryd W; Lindh M; Horal P
    J Clin Microbiol; 2011 Nov; 49(11):3794-9. PubMed ID: 21940473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion.
    Molden T; Kraus I; Karlsen F; Skomedal H; Nygård JF; Hagmar B
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):367-72. PubMed ID: 15734959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
    Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
    J Clin Microbiol; 2010 Aug; 48(8):2779-85. PubMed ID: 20573862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.
    Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij W; Snijders PJ; Meijer CJ
    Br J Cancer; 2012 Feb; 106(5):975-81. PubMed ID: 22251922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
    Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
    Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
    Bulk S; Bulkmans NW; Berkhof J; Rozendaal L; Boeke AJ; Verheijen RH; Snijders PJ; Meijer CJ
    Int J Cancer; 2007 Jul; 121(2):361-7. PubMed ID: 17354241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests-A prospective population-based register study.
    Reinholdt K; Juul KE; Dehlendorff C; Munk C; Kjaer SK; Thomsen LT
    Acta Obstet Gynecol Scand; 2020 Feb; 99(2):204-212. PubMed ID: 31562779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing.
    Sørbye SW; Fismen S; Gutteberg T; Mortensen ES
    PLoS One; 2010 Sep; 5(9):e12724. PubMed ID: 20856930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.